This protocol is designed to obtain detailed information on the impact of body composition on
the pharmacokinetic behavior of doxorubicin after a single intravenous dose in children 21
years of age or younger. There is no efficacy component. Approximately 9 children will be
enrolled at Children's Hospital Boston. The information gained from this study could be very
important in developing dosing strategies for doxorubicin in the obese patient population.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital
Collaborators:
Elizabeth Glaser Pediatric AIDS Foundation Glaser Pediatric Research Network